Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AMETEK, Inc. (AME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs AMETEK, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.72 (market cap $4.49B), while AMETEK, Inc. trades at $228.58 (market cap $53.11B). The key difference: AMETEK, Inc. is far larger — about 11.8× ACADIA Pharmaceuticals Inc.'s market cap, and AMETEK, Inc. pays a 0.59% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AME | |
|---|---|---|
Market Cap | $4.49B | $53.11B |
Sector | Health | Industrials |
52-Week High | $28.06 | $241.94 |
52-Week Low | $20.06 | $176.44 |
Enterprise Value | $3.69B | $54.80B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AME trades at $231.70, down 1.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $263.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.97 exceeding expectations. Revenue grew to $7.40 billion in 2025, and net income margin improved to 20.11%. Recent acquisitions, including First Aviation Services and the Indicor Instrumentation group for $5 billion, aim to expand its aerospace and industrial technology footprint.
The outlook for AME is positive, supported by earnings momentum, strategic acquisitions, and solid profitability. Risks include integration challenges from large acquisitions and elevated valuation multiples, such as a P/E of 35.82. With no sell ratings from analysts and institutional backing, the stock presents a growth opportunity, though investors should monitor execution on acquisition synergies and macroeconomic conditions affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
